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Abstract
Aims: We investigated whether radiation-induced nontargeted effects are involved in the cytotoxic effects of
anticell surface monoclonal antibodies labeled with Auger electron emitters, such as iodine 125 (monoclonal
antibodies labeled with 125I [125I-mAbs]). Results: We showed that the cytotoxicity of 125I-mAbs targeting the
cell membrane of p53+/+ HCT116 colon cancer cells is mainly due to nontargeted effects. Targeted and
nontargeted cytotoxicities were inhibited in vitro following lipid raft disruption with Methyl-b-cyclodextrin
(MBCD) or filipin or use of radical oxygen species scavengers. 125I-mAb efficacy was associated with acid
sphingomyelinase activation and modulated through activation of the AKT, extracellular signal-related kinase
½ (ERK1/2), p38 kinase, c-Jun N-terminal kinase ( JNK) signaling pathways, and also of phospholipase C-c
(PLC-c), proline-rich tyrosine kinase 2 (PYK-2), and paxillin, involved in Ca2+ fluxes. Moreover, the non-
targeted response induced by directing 5-[(125)I]iodo-2¢-deoxyuridine to the nucleus was comparable to that of
125I-mAb against cell surface receptors. In vivo, we found that the statistical significance of tumor growth delay
induced by 125I-mAb was removed after MBCD treatment and observed oxidative DNA damage beyond the
expected Auger electron range. These results suggest the involvement of nontargeted effects in vivo also.
Innovation: Low-energy Auger electrons, such as those emitted by 125I, have a short tissue range and are
usually targeted to the nucleus to maximize their cytotoxicity. In this study, we show that targeting the cancer
cell surface with 125I-mAbs produces a lipid raft-mediated nontargeted response that compensates for the
inferior efficacy of non-nuclear targeting. Conclusion: Our findings describe the mechanisms involved in the
efficacy of 125I-mAbs targeting the cancer cell surface. Antioxid. Redox Signal. 25, 467–484.
Introduction
The highly localized cytotoxicity of Auger elec-trons is particularly attractive for targeted radionuclide
therapy of microscopic or metastatic disease because it al-
lows the irradiation of tumor cells while sparing healthy
tissues. Auger electrons are produced in atoms decaying by
internal conversion or electron capture. These processes
create a vacancy in the inner electron shell that is subse-
quently filled by electrons dropping in from higher energy
levels. Thus, the vacancy moves to the outer shells, and the
transition is accompanied by cascades of complex emissions
of Auger, Coster–Kronig, and super Coster–Kronig electrons
(collectively called Auger electrons) and soft X-rays [for
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review, Kassis (25)]. The majority of Auger electrons have
very low energies (between a few eV and 1 keV) and thus
very short range in tissue (<1 lm). They release high amounts
of energy in a spherical volume of a few cubic nanometers
(46, 49, 54) and behave like medium-to-high linear energy
transfer (LET) radiation (4–26keV/lm). Hence, they produce
locally dense ionizations that are very destructive when in-
corporated into nuclear DNA (7, 22, 26–29) or the nucleus (1,
9, 12, 14, 15). Although they have high LET features, they have
been shown to contribute to cytotoxicity or DNA lesion for-
mation indirectly via reactive oxygen species (ROS) (63, 64).
The radionuclides iodine 125 (125I), iodine 123 (123I), and
indium 111 (111In) are the most widely used Auger electron
emitters for in vitro and in vivo studies. Clinical trials have
evaluated the efficacy, toxicity, or tumor distribution of Auger
electron emitters conjugated to (i) thymidine analogs that are
incorporated into the DNA of cells in S phase (18, 40, 41), (ii)
octreotide, a somatostatin analog targeting neuroendocrine and
other cancers (16, 31, 37), and (iii) monoclonal antibodies
(mAbs) with specificity for cancer cellular antigens (35, 52,
65) and human epidermal growth factor receptor (62). The
latter treatment is known as radioimmunotherapy (RIT).
Conventionally, Auger electron emitters are targeted to the
nucleus or DNA because it is considered that Auger electrons
need to be within the nucleus to achieve maximal cell kill.
Therefore, RIT using Auger electron emitters has been regarded
as comparatively disadvantageous because the localization of
the radionuclide, after receptor binding, is not the nucleus, but
the cytoplasm (internalizing mAbs) or the cell membrane
(noninternalizing mAbs).
However, we previously showed, using in vitro and in vivo
models, substantial antitumor efficacy of noninternalizing
monoclonal antibodies labeled with 125I (125I-mAbs). Fur-
thermore, the cytotoxicity of noninternalizing mAbs was
greater than that achieved by internalizing 125I-mAbs (50, 53)
and was not due to inefficient detection of DNA damage
related to low absorbed dosage. We proposed that, instead,
nontargeted effects could be involved (48). This is in agree-
ment with the work by Xue et al. in 2002 showing in vivo that
nontargeted effects are produced by LS174T cells radi-
olabeled with the DNA base analog 5-[(125)I]iodo-2¢-
deoxyuridine (125I-UdR), indicating that Auger electrons can
kill cells beyond their path length (66). Other reports indi-
cate that they have also been observed during radionuclide
therapy using tritiated thymidine (3H3H-dThd) (5), meta-
[211At]astatobenzylguanidine (211At-MABG), meta[123I]iodo-
benzylguanidine (123I-MIBG) (6), and 213Bi-mAbs (10).
Radiation-induced nontargeted effects (also called by-
stander effects) occur in cells that are not directly traversed
by ionizing particles, but are in contact with irradiated cells.
They have been mainly observed after low-dose (<0.5 Gy)
external beam radiotherapy (EBRT), for both low and high
LET irradiation, and are associated with a lack of dose–effect
relationships [for reviews, Hamada (19) and Prise and O’Sul-
livan (51)]. Bystander effects include cell death, DNA damage,
apoptosis (39), yield of micronuclei and chromosomal aberra-
tions (4, 43), and malignant transformation (55). The bystander
response depends both on the cell type and on radiation LET
and involves the release of soluble factors in the extracellu-
lar environment together with the transmission of signaling
molecules through gap junctions when cells are in contact
(33, 42). ROS and reactive nitrogen species (RNS), Ca2+ ions,
ATP, and cytokines have been shown to be involved (2, 38).
In this study, we show that oxidative stress-induced non-
targeted effects are involved in the cytotoxicity of 125I-mAbs
targeting cell surface receptors. This phenomenon involves
lipid raft formation followed by subsequent activation of
signaling pathways. Moreover, the potency of the cytotoxic
nontargeted effect induced by targeting the nucleus with 125I-
UdR was comparable to that resulting from exposure to 125I-
mAbs against cell surface receptors, suggesting that it was
independent of the localization of Auger electron emitters.
Finally, our data support the existence of nontargeted cyto-
toxic effects, both in vitro and in vivo.
Results
125I-mAbs induce nontargeted effects
Clonogenic survival of p53+/+ HCT116 cells targeted by
4MBq/ml of noninternalizing anti-carcinoembryonic antigen
(CEA) 125I-mAb (resulting in cell surface localization of 125I)
or internalizing anti-Human Epidermal Receptor type 1
(HER1) 125I-mAb (resulting in cytoplasmic localization of 125I)
(donor cells) was reduced to 58%– 2.5% and 57.8%–7%, re-
spectively. These values were significantly different (p< 0.001)
from values measured using the nonspecific 125I-PX mAb
(Fig. 1A, left panel). We also investigated the role of p53
by performing the same experiments in p53-/- HCT116 cells
and showed a similar reduction in clonogenic survival (to
54.6% – 1.2% and 56.5% – 1.9%, respectively) (Fig. 1B, left
panel). Again survival was statistically significantly different
from survival measured after nonspecific 125I-PX mAb exposure
(p<0.001), where no toxicity was observed (Fig. 1B, left panel).
To test whether nontargeted effects were involved in the
toxicity induced by 125I-mAb, nonirradiated p53+/+ and p53-/-
HCT116 cells (recipient cells) were incubated with medium in
which donor cells had been cultured for 2 h following a 2-day
exposure to 4MBq/ml of anti-CEA or anti-HER1 125I-mAbs.
Clonogenic survival of recipient cells was significantly reduced
when compared to that of cells incubated with medium from
cells exposed to nonspecific 125I-PX mAb ( p<0.01). For ex-
ample, in p53+/+ HCT116 recipient cells, survival decreased to
71.2%– 7.0% after incubation with medium from p53+/+
HCT116 donor cells exposed to anti-CEA 125I-mAb and to
70.6%– 8.4% after exposure to medium from cells exposed to
anti-HER1 125I-mAb (Table 1 and Fig. 1A, right panel). Simi-
larly, in p53-/- HCT116 recipient cells, survival decreased to
Innovation
Because of their physical properties, Auger electron
emitters, such as iodine 125 (125I), are usually targeted to
the nucleus to maximize their cytotoxicity. In this study,
we show that monoclonal antibodies labeled with 125I
(125I-mAbs) and targeting the cell membrane are cytotoxic
through oxidative stress-mediated nontargeted effects. As
this nontargeted response is comparable to that observed
with 125IdUrd, bystander effects induced by cell mem-
brane irradiation could compensate for the anticipated
inferior efficacy of the absence of nuclear targeting, par-
ticularly when vectors do not gain access to every tumor
cell. Furthermore, Auger emitter-labeled mAbs bypass the
disadvantages of using labeled deoxyribonucleotides.
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73.3%– 5.6% following incubation with medium from p53-/-
HCT116 donor cells exposed to anti-CEA 125I-mAb and to
74.5%– 5.1% upon switch to medium from cells exposed to
anti-HER1 125I-mAb (Fig. 1B, right panel).
No cell killing was observed after incubation of recipient
cells with medium from donor cells treated with the non-
targeting 125I-PX mAb (Fig. 1B, right panel) or with unlabeled
mAbs (Supplementary Fig. S1A; Supplementary Data are
available online at www.liebertpub.com/ars). This suggests that
the effect was specific and required 125I-mAb binding to the cell
surface. Similar results were obtained in A-431CEA (Fig. 1C)
and SK-OV-3CEA cells (Supplementary Fig. S1B) treated with
the same 125I-mAbs. Gamma-H2AX foci (markers of DNA
double strand breaks, DSBs) were detected in both p53+/+
HCT116 donor (exposed to anti-CEA or anti-HER1 125I-mAbs)
and recipient cells, again indicating the occurrence of non-
targeted effects in recipient cells (Fig. 2A, B). It must be noted
that cells were proliferating and that a larger number of gamma-
H2AX foci are likely to be produced during the S phase. The
proportion of donor cells showing foci was assessed to be about
10% in nonirradiated cells, while it increased up to 25% in
cells exposed to the nonspecific 125I-PX mAb and 100% after
exposure to the specific anti-HER1 and anti-CEA 125I-mAbs.
Corresponding values were 15% and 100% in recipient cells
(data not shown).
Nontargeted effects do not require cellular
internalization of 125I
Localization of the anti-CEA and anti-HER1 mAbs at the
cell membrane and cytoplasm, respectively, was confirmed
by cell fractionation followed by Western blotting (Fig. 2C)
and by immunofluorescence (Fig. 2D) in p53+/+ HCT116 and
A-431CEA cells. Coincubation of p53
+/+ HCT116 donor cells
with anti-CEA or anti-HER1 125I-mAbs and sodium azide, a
drug preventing antibody internalization after receptor
binding, did not modify the nontargeted response in recipient
cells (Fig. 2E). These results suggest that internalization of
125I is not required for radiation-induced nontargeted effects.
The role of lipid rafts in 125I-mAb cytotoxicity in vitro
Lipid rafts can be ceramide-enriched platforms in the cell
membrane that are produced through sphingomyelin hydro-
lysis to ceramide and phosphorylcholine following acid
sphingomyelinase (ASMase) activation by ROS (56). To
investigate whether 125I-mAbs affected the cell membrane
FIG. 1. Clonogenic sur-
vival. Clonogenic survival
was assessed in donor and
recipients cells 12 days fol-
lowing either exposure to ac-
tivities of 125I-mAbs from 0 to
4MBq/ml for 2 days (donor
cells) or incubation in culture
medium in which donor cells
had been cultured for 2 h (re-
cipient cells).Donor cellswere
treated with noninternalizing
125I-anti-CEA, internalizing
125I-anti-HER1, or nontarget-
ing 125I-PXmAbs.Clonogenic
survival was measured in (A)
p53+/+ HCT116, (B) p53-/-
HCT116, and (C) A-431CEA
cells. Results are the mean–
SD of four experiments per-
formed in triplicate. *p< 0.05,
**p< 0.01, ***p< 0.001 com-
pared with 125I-PX mAb-
treated cells. CEA, carci-
noembryonic antigen; HER1,
Human Epidermal Receptor
type 1; 125I, iodine 125;mAbs,
monoclonal antibodies; SD,
standard deviation.
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organization, the formation of lipid raft domains, as detected
by cholera toxin, was monitored in donor p53+/+ HCT116
cells exposed to 4MBq/ml of anti-CEA or anti-HER1 125I-
mAbs for 48 h. In these cells, lipid raft formation was in-
creased compared with nonirradiated cells (NT) or with cells
incubated with the irrelevant 125I-PX mAb (Fig. 3A). Flow
cytometric analysis showed that the membrane concentration
of ceramide (indicative of lipid raft formation) in cells ex-
posed to anti-CEA or anti-HER1 125I-mAbs was increased
compared with nonirradiated cells (NT) and cells treated
with unlabeled mAbs (Fig. 3B). Codetection of ceramide and
Annexin (apoptosis marker) by immunofluorescence was ob-
served in some of the p53+/+ HCT116 cells (Fig. 3C). How-
ever, we previously showed that apoptosis was not involved
in the cytotoxic effects of 125I-anti-CEA mAb (46).
The formation of ceramide was corroborated also by the
significantly higher ASMase activity measured in whole cell
lysates of p53+/+ HCT116 treated with anti-CEA or anti-
HER1 125I-mAbs (three times higher compared to unlabeled
mAbs, p < 0.001) (Fig. 3D). We also found that the level of
sphingosine-1-phosphate (S1P) resulting from hydrolysis of
ceramide was strongly increased in cells exposed to anti-CEA
or anti-HER1 125I-mAbs (Fig. 3E), while no such increase
was observed in control cells.
The involvement of lipid raft formation in 125I-mAb cyto-
toxicity was confirmed by the finding that lipid raft formation
was reduced in p53+/+ HCT116 donor cells coincubated with
anti-CEA or anti-HER1 125I-mAbs and filipin (a lipid raft
disruptive agent) compared with cells exposed only to 125I-
mAbs (Fig. 4A). Moreover, coincubation of donor cells with
filipin significantly reduced the formation of phosphorylated
histone H2AX (c-H2AX) foci in both donor and recipient
cells (Fig. 4B). Finally, 125I-mAb cytotoxicity in both donor
(Fig. 4C) and recipient cells (Fig. 4D)was significantly reduced
when donor cells were incubated in the presence of filipin.
Indeed, clonogenic survival increased from 58%– 2.5% to
84.4%– 2.6% and from 57.8%– 7% to 81.0%– 1.6% in donor
cells coincubated with 4MBq/ml anti-CEA or anti-HER1 125I-
mAbs and filipin, respectively (Table 1). In recipient cells,
survival increased from 71.2%– 7% to 92.8%– 2.3% and from
70.6%– 8.4% to 94.2%– 2.4%, respectively. Similar protec-
tion was afforded by methyl-b-cyclodextrin (MBCD), another
lipid raft disruptor (Supplementary Fig. S2). These findings
indicate that lipid raft formation is involved in both targeted and
nontargeted cytotoxicity of 125I-mAbs.
Phosphorylated proteins associated with 125I-RIT
To identify the signaling pathways activated in cells ex-
posed to anti-CEA or anti-HER1 125I-mAbs, the phosphor-
ylation profiles of 46 kinases were assessed by array-based
proteomics (Fig. 5 and Supplementary Fig. S3). Only extra-
cellular signal-related kinase ½ (ERK1/2) and C-AMP Re-
sponse Element-binding protein (CREB) were strongly
activated after treatment with unlabeled anti-CEA mAb
(Fig. 5A). Conversely, upon incubation with the unlabeled
anti-HER1 mAb, several proteins were induced, including
ERK1/2, CREB, p53, and AKT (Fig. 5B).
Thus, only the anti-CEA 125I-mAb was used to investigate
the effect of targeting 125I to the cell surface.When cells were
exposed to anti-CEA 125I-mAb (Fig. 5A), the ERK1/2, AKT,
p38, and c-Jun N-terminal kinase ( JNK) signaling pathways
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were induced. Activated downstream AKT proteins included
p70S6 kinase (p70S6K), glycogen synthase kinase 3 (GSK3),
and endothelial nitric oxide synthase (e-NOS) (61). Signal
transducer and activator of transcription (STAT) 1 and 4,
90 kDa ribosomal S6 kinase (RSK), mitogen- and stress-
activated protein kinase (MSK), and CREB proteins, which
are downstream targets of ERK1/2 signaling, were also ac-
tivated, as well as c-JUN, which is downstream of p38 and
JNK (for review (61)). Phosphorylated proteins involved in
Ca2+ fluxes, such as phospholipase C-c (PLC-c), proline-rich
tyrosine kinase 2 (PYK-2), and paxillin, were strongly acti-
vated by exposure to anti-CEA 125I-mAb. Phosphorylation of
AKT, p38, JNK, CREB, GSK3, STAT 1 and 4, e-NOS, MSK,
PLC-c, PYK-2, and paxillin was abolished, whereas phos-
phorylation of ERK1/2, c-JUN, p53, RSK, SAT 2, and
p70S6K was diminished in cells coincubated with filipin
(Fig. 5), confirming that these proteins are downstream ef-
fectors of lipid raft formation and, thus, are likely to be in-
volved in 125I-mAb nontargeted effects. Moreover, the use of
different pharmacological inhibitors of MEK (U0126) and
subsequently of downstream ERK1/2 signaling pathway,
PI3K (ZSTK474) and subsequently of downstream AKT
signaling pathway, p38 (SB203580), and JNK (SP600125)
indicated that, among the identified proteins activated, p38
and JNKwere mainly involved in the response of cells to 125I-
mAb exposure (Fig. 6). No effect of EGTA on clonogenic
survival was observed (Supplementary Fig. S1C).
ROS are involved in Auger electron-induced
nontargeted response
The involvement of ROS in the mediation of the bystander
response was examined by culturing recipient cells in me-
dium from p53+/+ HCT116 donor cells that had been treated
FIG. 2. Gamma-H2AX foci
detection and optional role of
125I-mAb internalization for
nontargeted cytotoxicity. (A)
Detection of gamma-H2AX
foci in p53+/+ HCT116 donor
(top panels) and recipient cells
(bottom panels) by immuno-
fluorescence assay. (B) The
number of foci per cell was
counted in 100 cells. Anti-
body localization was as-
sessed in p53+/+ HCT116 and
A-431CEA cells by (C) sub-
cellular fractionation and (D)
immunofluorescence. F-actin
was stained with conjugated
phalloidin (Red) to visualize
cytoplasm, nucleiwithHoechst
(Blue), and mAbs with Alexa-
488-conjugated anti-mouse sec-
ondary mAbs. (E) Clonogenic
survival was assessed in p53+/+
HCT116 donor cells coincu-
batedwith 0.02% sodiumazide
(a drug blocking antigen inter-
nalization) and a range of
activities of 125I-mAbs (non-
internalizing anti-CEA, internal-
izinganti-HER1,ornontargeting
PX mAbs). Clonogenic survival
of recipient cells was assessed
after incubation with condi-
tionedmediumfromdonor cells
exposed to 125I-mAbs in the
presence of sodium azide. Re-
sults are themean–SDof three
experiments performed in trip-
licate. *p< 0.05, **p< 0.01,
and ***p< 0.001 compared to
NT cells (B) or to the 125I-PX
mAb-treated cells (E). Mb,
membrane; Cyto, cytoplasm.
To see this illustration in color,
the reader is referred to the
web version of this article at
www.liebertpub.com/ars
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with 125I-mAbs in the presence or absence of the free radical
scavengers dimethyl sulfoxide (DMSO) or N-acetylcysteine
(NAC) (Fig. 7). We previously checked (using immunoflu-
orescence detection of mAbs in the presence of cells grown
on coverslips) that NAC did not prevent anti-HER1 or anti-
CEA mAbs from binding to their receptors.
Survival of both donor and recipient cells was significantly
increased compared with controls treated with 125I-mAbs in
the absence of free radical scavengers ( p< 0.001 and p< 0.01,
respectively). This suggests that oxidative stress is involved in
both targeted and nontargeted cytotoxic effects of 125I-mAbs.
Nontargeted effects of 125I directed to the cell
membrane or the nucleus are equipotent
To compare the effect of targeting 125I to the cell membrane or
the nucleus, p53+/+HCT116 donor cells were incubatedwith 125I-
UdR (nuclear localization of 125I) or with anti-CEA or anti-HER1
FIG. 3. Lipid rafts are formed upon exposure to 125I-mAbs via ASMase-induced ceramide formation. (A) Lipid rafts were
detected by immunofluorescence analysis using Alexa-488-conjugated cholera toxin (a marker of lipid raft) in untreated (NT) and
treated p53+/+ HCT116 cells (noninternalizing 125I-anti-CEA, internalizing 125I-anti-HER1, nontargeting 125I-PX mAbs). (B) Cer-
amide was measured in p53+/+ HCT116 cells by flow cytometry analysis after treatment with unlabeled mAbs (top panels), or with
125I-mAbs (bottom panels). Ctrl+, positive control (100ll of 0.4U/ml Bacillus cereus SMase and 10ll sphingomyelin). (C)
Colocalization of ceramide and Annexin V in apoptotic cells was determined by immunofluorescence, in untreated (NT) and 125I-
anti-CEA-treated p53+/+ HCT116 cells. (D) ASMase activity was determined in whole p53+/+ HCT116 cell lysates using the
Amplex Red Sphingomyelinase Fluorimetry Kit after incubation with unlabeled or 125I-mAbs. Ctrl+, positive control (100ll of
0.4U/ml B. cereus SMase and 10ll sphingomyelin); Ctrl- (Amplex Red working solution without sphingomyelin). (E) S1P
concentration was determined in whole p53+/+ HCT116 cells lysates using the Sphingosine-1-Phosphate Assay Kit after incubation
with unlabeled or 125I-mAbs or in nontreated cells (NT). Results are the mean–SD of four experiments performed in triplicate.
**p<0.01 and ***p<0.001 compared to cells treated with unlabeled mAbs. ASMase, acid sphingomyelinase; S1P, sphingosine-1-
phosphate. To see this illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/ars
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125I-mAbs. Subsequently, clonogenic survival was assessed in
both donor and recipient cells. Results are summarized in Table 1.
The uptake of 125I-UdR and 125I-mAbs was measured for every
test activity for 6 days, and the total number of decays occurring in
cellswascalculatedasdescribedpreviously (46).The resultsof the
clonogenic survival assay showed that, in donor cells, 125I-UdR
(nuclear localization) was more cytotoxic than anti-CEA (cell
surface localization) or anti-HER1 (cytoplasm localization) 125I-
mAbs. Conversely, in recipient cells, cell survival was similar and
independent of 125I localization, indicating that 125I at the cell
membrane is as efficient as nuclear 125I in killing bystander cells.
The role of lipid rafts in 125I-mAb cytotoxicity in vivo
Mice bearing intraperitoneal tumor xenografts were treated
with NaCl, anti-CEA mAb (100lg/injection at day 8 and 11),
125I-anti-CEA mAb (37MBq/injection at day 8 and 11), or
MBCD (300mg/kg; daily, from day 6 to 15), or with both125I-
anti-CEA mAb and MBCD. At day 30, tumor mass was signifi-
cantly reduced in thegroup treatedwith 125I-anti-CEAmAb(RIT)
compared with the NaCl group (p=0.0227). No difference was
observed between the groups treated with MBCD, NaCl
(p=0.9349), or anti-CEAmAb(p=0.9563).The latter result is in
agreement with a previously published study indicating that anti-
CEA mAbs have no effect on mouse tumor growth (53). Treat-
ment with MBCD removed the statistical significance of RIT-
induced tumor growth delay such that no differencewas observed
between NaCl and RIT+MBCD groups (p=0.2481) (Fig. 8A).
Oxidative DNA damage occurs beyond the range
of Auger electrons in vivo
Digital autoradiographic analysis performed on sections of
tumors collected in mice injected with 125I-anti-CEA mAb
FIG. 4. Role of lipid rafts in
the nontargeted response. (A)
Disruption of lipid rafts was
confirmed by immunofluores-
cenceanalysis usingAlexa-488
(Green)-conjugated cholera
toxin (amarker of lipid rafts) in
p53+/+ HCT116 cells coin-
cubated with 125I-mAbs (non-
internalizing anti-CEA or
internalizing anti-HER1) and
filipin. Nuclei were stained
with Hoechst (Blue). (B) Ima-
ges of gamma-H2AX foci
(immunofluorescent detection
of Alexa-488 [Green] conju-
gated anti mouse-anti gamma-
H2AX antibody) in p53+/+
HCT116 donor cells incubated
2 days with 125I-mAbs in the
presence or absence of filipin
(top panels) and in the corre-
sponding recipient cells (bot-
tom panels). The number of
foci per cell was counted in 100
cells. Clonogenic survival was
assessed in p53+/+ HCT116
donor cells coincubated for
2 days with and without 125I-
mAbs andfilipin (C), and in the
corresponding recipient cells
(D). Results are the mean–SD
of four experiments performed
in triplicate. *p<0.05, **p<
0.01, ***p<0.001compared to
cells treated with 125I-mAbs.
To see this illustration in color,
the reader is referred to the
web version of this article at
www.liebertpub.com/ars
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showed that radioactivity (and thus the absorbed dose) was
mainly localized at the tumor periphery in A-431CEA tumor
cell xenografts (Fig. 9A, inset in the bottom left corner).
Conversely, DNA DSBs occurred homogeneously through-
out the tumor, as indicated by immunofluorescence detection
of p53-binding protein 1 (53BP1), a DNA damage sensor that
is recruited to damaged chromatin (Fig. 9A). The average
number of foci per cell was 4.4 at the center and 4.3 at the
periphery of the tumor. The corresponding regional activi-
ties were 2.3 and 34.7 cpm per mm2. Our observation of
similar levels of DNA DSBs at the center of the tumor,
independent of the absorbed dose and beyond the range of
Auger electrons, supports the involvement of nontargeted
effects also in vivo. 53BP1 expression was also investigated
in A-431CEA tumor cell xenograft sections from mice in-
jected with the irrelevant 125I-PX mAb (Fig. 9B). The
numbers of foci per cell was 0.8 (tumor center) and 1.0
(tumor periphery). These values were lower than those ob-
served following treatment with anti-CEA 125I-mAb, de-
spite the higher uptake of 125I-PX mAb exemplified by
activity per area values of 28 and 18.2 cpm/mm2 at the
tumor center and periphery, respectively. A similar level of
0.7 –– 0.1 53BP1 foci was found in tumors of NaCl or anti-
CEA-treated mice (Fig. 9C).
This ruled out the possibility that the signal detected in
tumors treated with anti-CEA 125I-mAb was caused by non-
specific induction of 53BP1 due to cross-irradiation from the
radioactivity present in nonmalignant regions of the animal.
Discussion
In the present study, we show that 125I translocation to the
nucleus is not required for cell killing and that radiation-
induced nontargeted effects contribute to 125I cytotoxicity
when labeled with monoclonal antibodies (125I-mAbs) (Ta-
ble 1). We also identify the signaling pathways involved in
these nontargeted effects. In particular, we show using p53-/-
and p53+/+ HCT116 cells that the latter protein did not play a
FIG. 5. Signaling path-
ways activated in 125I-mAb-
treated p53+/+ HCT116 cells
and role of oxidative stress
in the nontargeted response.
(A) Signaling pathways acti-
vated after incubation of p53+/
+ HCT116 donor cells with
unlabeled anti-CEA, anti-CEA
125I-mAbs, or anti-CEA 125I-
mAbs and filipin. (B) Signal-
ing pathways activated after
incubation of p53+/+ HCT116
donor cells with unlabeled
anti-HER1, anti-HER1 125I-
mAbs, or anti-HER1 125I-
mAbs and filipin. The Human
Phospho-Kinase array (Pro-
teome Profiler Array; R&D
Systems, Minneapolis, MN)
was used to detect the phos-
phorylation level of 46 ki-
nases. For each kinase, the
Image J software was used to
determine pixel number. To
see this illustration in color,
the reader is referred to the
web version of this article at
www.liebertpub.com/ars
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significant role in anti-CEA 125I-mAb cytotoxicity since no
difference was observed between the two cell lines (Fig. 1A,
B and Supplementary Fig. S4). We chose the nuclear p53
protein as it is one of the main proteins involved in signaling
pathways activated by nuclear damage.
The potency of nontargeted cell kill, assessed using a
medium transfer protocol, was independent of 125I localiza-
tion (nucleus, cytoplasm, or cell surface) and of the magni-
tude of targeted cytotoxicity in donor cells (Table 1). In our
in vitro experimental RIT model, donor cells were incubated
with 125I-mAbs and were killed both by targeted and non-
targeted effects. Therefore, it is possible to determine the
relative contribution of targeted and nontargeted cytotoxicity
to donor cells by comparing the survival values of donor and
recipient cells reported in Table 1. As death of recipient cells
(incubated in culture medium in which donor cells had been
cultured for 2 h) ranged between 28.8% and 29.4% (Fig. 1B),
it may be assumed that a similar (or even higher) magnitude
of nontargeted effects also occurred in donor cells that were
directly exposed to 125I-mAbs for 48 h. Accordingly, cell
death by targeted effects in donor cells would be equal to or
less than 13.2% (42.0% minus 28.8%) and 12.8% (42.2%
minus 29.4%) for 125I localized at the cell surface or cyto-
plasm, respectively, and equal to or less than 50.7% (77.9%
minus 27.2%) for 125I within the nucleus (Table 1). These
data confirm the greater cytotoxicity of 125I when incorpo-
rated into DNA (22, 17, 64) in cells that are directly targeted.
Our results indicate that the cell membrane plays a major
role not only in the targeted cytotoxic effects of 125I-mAbs
but also in nontargeted cytotoxic effects (Fig. 1). According
to the fluid mosaic model (57), the membrane contains
sphingolipids (predominantly sphingomyelin), cholesterol,
and glycophospholipids. Sphingolipids associate with each
other and with cholesterol to form sphingolipid- and
FIG. 6. Pharmacological
inhibitors of MAPK path-
ways. p53+/+HCT116 donor
cells were incubated for 48 h
with 125I-anti-CEAmAb in the
presence of (A) SB203580
(p38 inhibitor), (B) SP600125
(JNK inhibitor), (C) ZSTK474
(PI3K inhibitor and indirectly
of its downstream AKT path-
way), or (D) U0126 (MEK1/2
inhibitor and indirectly of its
downstream ERK1/2 path-
way). Results are the mean–
SD of four experiments per-
formed in triplicate. *p<0.05,
**p< 0.01, compared to cells
treated with 125I-mAbs. ERK1/
2, extracellular signal-related
kinase ½; JNK, c-Jun N-
terminal kinase; MAPK,
mitogen-activated protein ki-
nase.
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cholesterol-enriched domains called lipid rafts that are sta-
bilized in some cells by caveolin (32). It has been shown that
ASMase activated by hydroxyl radicals (56) translocates
from the cytoplasm to the outer layer of the cell membrane,
where it hydrolyzes sphingomyelin into hydrophobic cer-
amide and hydrophilic phosphorylcholine (59, 68). Ceramide
production is accompanied by the coalescence of lipid raft
microdomains into ceramide-enriched large platforms that
can participate in the spatial reorganization of membrane
receptors and in the activation of multiple signaling path-
ways. Several mechanisms leading to protein activation
through membrane reorganization have been identified in
response to EBRT (8, 13, 47).
Our results confirm that similar mechanisms might be in-
volved in 125I-mAb efficacy after binding to the cell surface
because we show that the localized energy deposition asso-
ciated with 125I decays was accompanied by ASMase acti-
vation (Fig. 3D), formation of ceramide-enriched large
platforms (Fig. 3A), and subsequent activation of signaling
pathways (Fig. 5). ROS scavenging or disruption of lipid
rafts, using MBCD or filipin, reduced not only the targeted
cytotoxic effect of 125I-mAbs but also the nontargeted cyto-
toxic effect (Figs. 4 and 7). The use of filipin, a cholesterol-
depleting agent, reduced the cytotoxic effect of 4MBq/ml
anti-CEA or anti-HER1 125I-mAbs by about half in donor
cells and by 75%–80% in recipient cells (Table 1), showing
the involvement of lipid rafts in the cytotoxic effects of 125I-
mAbs. These results are supported by in vivo data showing
that MBCD treatment removes the statistical significance of
the therapeutic efficacy of 125I-anti-CEA mAb (Fig. 8).
A schematic representation of the mechanisms that might
be involved in 125I-mAbs targeted cytotoxicity is proposed in
Figure 10. Formation of ceramide-enriched large platforms is
induced following ASMase activation mediated by ROS (56)
originating from water radiolysis (presumably in a dose-
dependent manner) (Fig. 3D). ROS could also be generated
FIG. 7. Oxidative stress is
involved in direct and non-
targeted cytotoxicity: Effect
of NAC on RIT-induced ef-
fects. p53+/+ HCT116 donor
cells were coincubated for
2 days with 50lM NAC or
0.5% DMSO and 125I-anti-
CEA (A, C, respectively) or
125I-anti-HER1 (B, D, respec-
tively) mAbs. Clonogenic
survival of the donor cells and
of the corresponding recipient
cells was measured. Results
are the mean–SD of four ex-
periments performed in tripli-
cate. *p< 0.05, **p< 0.01,
***p< 0.001 compared to
cells treated with 125I-mAbs.
DMSO, dimethyl sulfoxide;
NAC, N-acetyl-L-cysteine;
RIT, radioimmunotherapy.
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following lipid raft-mediated activation of NAD(P)H oxidase
(36, 67). ROS contribute to ‘‘chronic’’ oxidative stress and
the subsequent DNA damage, including the formation of
micronuclei in nontargeted cells (3, 44). This is in agreement
with our previous finding that the abundance of micronuclei
in cells exposed to 125I-mAbs was not correlated with the
mean absorbed dose to the nucleus (48, 50). The involvement
of oxidative stress in EBRT-induced nontargeted effects has
been extensively reviewed by Havaki et al. (20). Irradiated
cells produce ROS and RNS through radiolysis and cyto-
kines. ROS and RNS are then directly transmitted to by-
stander cells through gap junctions or through release in the
extracellular medium (20). In bystander cells, different sig-
naling pathways participate in the upregulation of genes en-
coding cytokines, cyclooxygenase-2 (COX2), and inducible
nitric oxide synthase (iNOS) that generate intracellular ROS
and RNS (20). However, the involvement of such mecha-
nisms following low dose rate and protracted exposure (as in
RIT) needs to be confirmed. The present study focused on the
mechanisms involved in irradiated donor cells, and we as-
sume that the main source of oxidative stress was associated
with radiation and hydroxyl radical formation. Elucidation of
the precise mechanisms involved in recipient cells would
require further work.
It is noteworthy that 125I decays must occur at the surface
of targeted cells to initiate the nontargeted response. Indeed,
our data show that low LET radiation (including electrons
and soft X-rays) emitted by the irrelevant PX 125I-mAb,
which does not interact with cells, did not produce a signif-
icant nontargeted response. This suggests that nontargeted
effects are induced mainly by high LET Auger electrons (of
very low range) generated at the cell surface when 125I-mAbs
bind to CEA or HER1 receptors.
The relative contribution of the various signaling pathways
activated by cell membrane reorganization following lipid
raft formation is complex and remains to be elucidated. We
show that the mitogen-activated protein kinases (MAPKs),
ERK1/2, P38, JNK, and AKT, and their downstream proteins,
are activated during exposure to 125I-mAbs. The role of these
kinases in our model is still unclear because AKT and ERK1/
2 promote cell survival, while ceramide, p38, JNK, and its
downstream target c-JUN participate in cell death. However,
the use of p38 or (to a lesser extent) of JNK inhibitors was
accompanied by a stronger effect on clonogenic survival (in-
crease) than the use of PI3K or MEK inhibitors, suggesting the
cell death mechanisms predominate (Fig. 6). We also found
that S1P, the hydrolysis product of sphingosine that is gener-
ated from ceramide by ceramidase (Figs. 3E and 10), was up-
regulated following exposure to anti-CEA 125I-mAb. Contrary
to ceramide, S1P inhibits apoptosis and stimulates cell prolif-
eration through activation of the AKT and e-NOS pathways
[for review, Oskouian and Saba (45)]. Paxillin also was acti-
vated by incubation with anti-CEA 125I-mAb (Fig. 5). Paxillin
can be phosphorylated by focal adhesion kinase (FAK) or
PYK-2, and phosphorylated paxillin serves as a scaffold protein
to facilitate the functional integration of focal adhesion pro-
teins. Paxillin is phosphorylated during EBRT as a downstream
protein target (together with AKT and ERK1/2) of FAK (21).
Moreover, our data suggest a possible role of ion channels
located in lipid rafts, such as Ca2+ channels. The role of Ca2+ in
EBRT-associated nontargeted effects has clearly been dem-
onstrated (38). The influx of extracellular Ca2+ can be regulated
by ceramide (11), but also by PLC-c that is activated upon
exposure toanti-CEA125I-mAb (Fig. 5A).DuringEBRT,PLC-
c localized at the plasma membrane produces inositol tri-
phosphate (IP3) that consequently induces Ca2+ release from
the endoplasmic reticulum through IP3 receptors (60). Such an
increase in Ca2+ cytoplasmic concentration could also con-
tribute to the phosphorylation of PYK-2 observed in cells ex-
posed to anti-CEA 125I-mAb (Fig. 5A) (34). PYK-2, a member
of the FAK family, is involved in cell proliferation and phos-
phorylates paxillin. However, incubation of donor cells with
EGTA, a chelator of extracellular calcium, was not accompa-
nied by modifications in clonogenic survival. In a previous
study, Lyng et al. have used EGTA in combination with ve-
rapamil and nifedipine to block also voltage-dependent cal-
cium channels (38) to investigate the role of Ca2+ ions. Such an
approach merits further investigation in our models also.
Finally, we investigated in A-431CEA tumor xenografts
from mice injected with anti-CEA 125I-mAb whether the
induction of DNA DSBs could be correlated with the
FIG. 8. In vivo therapeutic efficacy of 125I-mAbs with
or without MBCD. (A) Mice bearing intraperitoneal A-
431CEA tumor xenografts were treated with NaCl, unlabeled
anti-CEA mAb (100lg/injection at day 8 and 11), or with
125I-anti-CEA mAb (RIT) at day 8 and 11 postgraft, daily
with MBCD from day 6 to 15 postgraft (MBCD), or with
125I-anti-CEA mAb (day 8 and 11 postgraft) and MBCD
(daily from day 6 to 15 postgraft) (RIT+MBCD) (n = 8 mice/
group). Tumors were collected at days 30 postgraft, and the
total tumor mass was determined. (B) The level of 53BP1
was determined by immunofluorescence in cryocut slices of
tumors of mice treated with 37MBq of 125I-anti-CEA mAbs,
125I-PX mAbs (RIT), or with NaCl. The level was deter-
mined in 100 cells of a selected area and was correlated
with the level of radioactivity (cpm/mm2) of the same area.
Between 6 and 7 areas of tumors in different mice were
selected. In A, results are the mean–SD of eight values.
*p < 0.05 compared to mice treated with NaCl. 53BP1, p53-
binding protein 1; MBCD, methyl-b-cyclodextrin.
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distribution of radioactivity. We observed that radioactivity
was mainly localized at the periphery of tumors, whereas
DNA DSBs were homogenously distributed throughout the
tumor (Figs. 8B and 9A).
A lower DSB induction was detected after 125I-PX mAb
treatment, despite the higher nonspecific uptake of radioac-
tivity, for some of the tumors, compared to anti-CEA 125I-
mAb. These data indicate that the DSBs observed after
treatment with anti-CEA 125I-mAb were not due to nonspe-
cific irradiation. Indeed, we analyzed 125I-PX mAb-treated
tumors showing high tumor uptake to be able to exclude the
possibility that DNA DSBs measured in the center of the
tumor were caused by nonspecific irradiation of 125I (mainly
soft X-rays and electrons) from the tumor periphery to the
center. We could also exclude any contribution from blood
circulating 125I-mAbs in mouse. As the major contribution to
the absorbed dose from 125I is due to Auger electrons, ra-
dioactivity distribution may be considered to be indicative of
the distribution of the absorbed dose. The reason for the
observed higher uptake in some areas of tumor of 125I-PX
mAb-treated mice compared with those treated with 125I-
anti-CEA mAb (especially the center) is unclear.
It could be that while the nonspecific antibody is able to
freely diffuse to the center of the tumor, the CEA binding
antibody binds to receptors, and the first of those encountered
would be in the periphery. Unless these receptors in the pe-
riphery become saturated, substantial penetration of further
unbound antibody molecules would be prevented. Notwith-
standing this effect, whatever the distribution of radioactiv-
ity, we have previously shown that 125I-PX mAb does not
have a therapeutic effect in vivo (53). Accordingly, our re-
sults indicate that DNADSB formation did not correlate with
FIG. 9. Radioactivity dis-
tribution and 53BP1 in-
duction do not overlap in
A-431CEA tumor cell xeno-
grafts treated with 125I-
anti-CEA mAbs. Digital
autoradiography (inset on the
bottom left side of each pan-
el) and immunohistochemi-
cal detection of 53BP1 in
tumor sections from mice
xenografted intraperitoneally
with A-431CEA cells and
treated 24 h before tissue
collection with a single in-
traperitoneal injection of
37MBq of (A) 125I-anti-CEA
mAb, (B) 125I-anti-PX mAb,
or (C) injected with NaCl.
The distribution of 53BP1
foci was determined in 100
cells of relevant areas of tu-
mors. Between 6 and 7 areas
of tumors in different mice
were selected. To see this il-
lustration in color, the reader
is referred to the web ver-
sion of this article at www
.liebertpub.com/ars
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the absorbed dose and that DNA damage occurred to a similar
extent both within and beyond the range of the 125I Auger
electrons. In a similar approach using 212Pb-mAbs for treat-
ing A-431CEA tumor xenografts, we also observed that dis-
tribution of DNA damage and induction of abnormal mitosis
do not correlate with tumor absorbed dose, a phenomenon not
observed with 212Pb-PX nonspecific mAb (data not shown).
These data support the involvement, in vivo, of nontargeted
effects during 125I-mAb RIT, but this needs to be confirmed
in further experiments.
One of the issues raised by our study is related to radiation
protection since nonirradiated tissues can show DNA damage
and subsequent possible cell death or cell transformation. This
may have implications for nuclear medicine where about one
atom in two (99mTc, 123I, 125I, 201Tl, 51Cr, 67Ga, etc.) emits
Auger electrons associated with other particles. It was gener-
ally considered that Auger binding DNA, or localized in the
cell nucleus, produces high LET radiation. However, there is
no guidance on how to calculate the equivalent dose for these
radionuclides. It has been proposed by the American Asso-
ciation of Physicists in Medicine that the component of dose
from the Auger electrons for radionuclides bound to DNA
should be given a preliminary radiation weighting factor of 10
for deterministic effects and 20 for stochastic effects for nu-
clear localization while ICRP has recommended considering
each situation (isotope and localization) separately (23, 24).
The dose equivalent calculated with these weighting factors
must be modulated by experimentally determined subcellular
distributions of the Auger electron emitters. Our study indi-
cates that the nontargeted effect of Auger electron emitters
bound to the cell surface has to be considered.
In conclusion, we have shown that Auger electron emitters,
such as 125I, conjugated to mAbs directed against the cancer
cell surface can be cytotoxic by a cell oxidative, stress-
FIG. 10. Schematic of the
mechanisms involved in
RIT using 125I-mAbs. 125I-
mAbs targeting the cell
membrane deliver high and
localized energy at the cell
surface. ASMase is activated
byROSproduced by radiation
energy deposition. ASMase
catalyzes sphingomyelin hy-
drolysis to ceramide and
phosphorylcholine. Ceramide
modifies the cell membrane
biophysical properties and
participates in the coales-
cence of sphingolipid- and
cholesterol-enriched domains
(called lipid rafts) into large
ceramide-enriched platforms,
leading to cell membrane re-
ceptor reorganization and ac-
tivation of the ERK1/2, AKT,
p38/JNK signaling pathways,
and their downstream targets.
Activation of phospholipase
C-c and of Ca2+-dependent
PYK-2 and paxillin is also ob-
served. Lipid raft-dependent
radiation-induced nontargeted
effects, including cytotoxicity
and cH2AX formation, are
observed in neighboring cells,
whatever the localization of
125I (cell surface or nucleus)
and independently of the decay
number (1047 Bq$s for 125I-
mAbs and 441 Bq$s for 125I-
UdR). Nontargeted effects are
strongly reduced by filipin or
MBCD. 125I-UdR, 5-[(125)I]
iodo-2¢-deoxyuridine; PLC-c,
phospholipase C-c; PYK-2,
proline-rich tyrosine kinase 2;
ROS, reactive oxygen species.
To see this illustration in color,
the reader is referred to theweb
version of this article at www
.liebertpub.com/ars
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mediated nontargeted mechanism involving lipid rafts. This
nontargeted effect is comparable to that induced by 125I-UdR
concentrated in the nucleus of tumor cells. Compared with
125I-UdR, lower targeted cytotoxicity is expected when using
125I-mAbs, but the induction of nontargeted effects could
compensate for the inferior efficacy of non-nuclear targeting.
Moreover, 125I-mAbs should also be less toxic toward pro-
liferating normal tissue, thus allowing an increase in the in-
jected activities.
These findings are particularly relevant for targeted therapy
in which vectors cannot gain access to every tumor cell. Their
extrapolation to targeted alpha radiotherapy, now routinely
used in clinical radionuclide therapy, should be evaluated.
Materials and Methods
Cell lines
A-431CEA and SK-OV-3CEA cells were obtained by
transfecting A-431 vulvar squamous and SKOV-3 ovarian
carcinoma cells (from ATCC, Molsheim, France), respec-
tively, using vectors encoding the CEA. p53+/+ HCT116
colon adenocarcinoma cells were obtained from ATCC. The
p53-/- HCT116 cell line was a kind gift from Professor Bert
Vogelstein. HCT116 cells were grown in RPMI 1640 me-
dium supplemented with 10% (v/v) fetal calf serum (FCS),
2mM l-glutamine, and antibiotics (0.1U/ml penicillin and
100 lg/ml streptomycin) at 37C in a humidified atmosphere
with 5% CO2. A-431CEA and SKOV-3CEA cells were grown
as described (50). All cell culture reagents were from Life
Technologies (Thermo Fisher Scientific, Waltham, MA).
Radiolabeled vectors for cell targeting
To target the cytoplasm, 125I was coupled to the internal-
izing mouse m225 mAb. 125I-labeled m225 mAb is inter-
nalized within the cytoplasm after binding to its receptor
(HER1). For cell surface localization, 125I was coupled to the
noninternalizing mouse IgG1kmAb 35A7. For the CEAGold
2 epitope (50), 35A7 is specific. The nonspecific PX antibody
was used as a control (irrelevant antibody). PX is an IgG1
mAb purified from mouse myeloma P3-X63 cells (30). The
three mAbs were obtained from mouse hybridoma ascites
fluids by ammonium sulfate precipitation followed by ion
exchange chromatography on DE52 cellulose (Whatman,
Balston, United Kingdom).
Antibody radiolabeling was performed according to the
IODO-GEN (1,3,4,6-tetrachloro-3a, 6a-diphenylglycoluryl)
(Sigma-Aldrich, St. Louis, MO) method (50). 125I-mAb-
specific activity was 370MBq/mg of protein, and immuno-
reactivity was 60%–95%. All experiments used 125I-mAb
activities £4MBq/ml. 125I was targeted to the nucleus using
the thymidine base analogue 125I-UdR at a specific activity of
81.4 TBq/mmol. 125I-UdR was purchased from PerkinElmer
(Waltham, MA).
RIT, medium transfer, and clonogenic survival
of irradiated and nonirradiated cells
p53+/+ or p53-/- HCT116, SK-OV-3CEA, and A-431CEA
cells were cultured in 6-cm Petri dishes (100–500 cells/dish)
with 3ml of medium. The following day, cells were incu-
bated with 125I-mAbs at activities £4MBq/ml for 48 h (donor
cells). For targeting of the nucleus, due to the higher toxicity
of 125I-UdR, between 100 and 1200 p53+/+ HCT116 cells
were seeded in 6-cm Petri dishes containing 3ml of medium
and exposed, the following day, to 125I-UdR activities of £20
kBq/ml for 48 h. Culture medium was then removed, and
cells were washed twice with 4ml phosphate buffered saline
(PBS). For clonogenic assays, performed as described in (50),
fresh medium (3ml) was added and donor cells were cultured
for 12 days. For investigating the nontargeted response, fresh
medium (3ml) was added to donor cells for 2 h and then
transferred to dishes in which cells had been seeded the day
before (recipient cells: 100–500 cells/6 cm dish). The trans-
ferred medium was checked for radioactivity (values were
generally very low, comprising between 0.08% and 0.10% of
the activity incubated with donor cells). Donor and recipient
cells were then grown for 12 days and colonies stained with
crystal violet (2.5 g/l in 45:5 30% [v/v] methanol/parafor-
maldehyde). Colonies containing 50 or more cells were
scored, and the surviving fraction was calculated. The tox-
icity of unlabeled mAbs was assessed using the same ex-
perimental conditions.
Drug treatment
To determine the role of mAb internalization in the by-
stander response, p53+/+ HCT116 cells were exposed for
2 days to 125I-mAbs of activity concentration £4MBq/ml in
the presence of 0.02% (w/v) sodium azide, a drug that blocks
mAb transport into the cytoplasm.
The role of cell membrane lipid raft formation in 125I-
mAb-induced bystander effects was investigated by coin-
cubating p53+/+ HCT116 donor cells with 125I-mAbs and
4mM MBCD (Sigma-Aldrich) for 6 h or with 2.5 lg/ml fi-
lipin (Sigma-Aldrich) overnight.
The potential role of oxidative stress in the induction of
bystander effects was assessed by coincubating p53+/+
HCT116 donor cells with 125I-mAbs and 50lM NAC
(Sigma-Aldrich) (for 2 days) or 0.5% DMSO (Sigma-
Aldrich) (overnight).
Immunofluorescence analysis of mAb localization, lipid
rafts, and gH2AX foci
For immunofluorescence studies, p53+/+ HCT116 cells were
plated on 12-mm glass coverslips in culture dishes. They were
fixed in 3.7% (v/v) formaldehyde and then permeabilized in
0.1% (v/v) TritonX-100 for 15min followed by incubationwith
1% (v/v) PBS/bovine serum albumin (BSA) for 1 h. To confirm
the mAb localization, an Alexa-488-conjugated anti-mouse
secondary mAb was used at a dilution of 1:200 (Invitrogen,
Saint Aubin, France). F-actin was stained with conjugated
phalloidin (1:5000; Sigma-Aldrich), and nuclei with 0.1lg/ml
Hoechst (Sigma-Aldrich). To visualize lipid rafts, p53+/+
HCT116 cells were incubated with Alexa-488-conjugated
cholera toxin (Sigma-Aldrich) at a dilution of 1:1000. cH2AX
foci were quantified in p53+/+ HCT116 cells after exposure
to 125I-mAbs for 2 days according to previously described
methodology (48). For immunofluorescent colocalization of
ceramide and apoptosis marker, cells were incubated with anti-
ceramide 15B4 antibody at dilution 1:10 (Alexis Biochemicals,
Heidelberg, Germany) for 1 h at 37C followed by three PBS
washing steps and incubation with PE-conjugated goat anti-
mouse IgM at a dilution of 1:200 (Jackson Immuno Research,
Baltimore, PA) and annexin V conjugated with FITC dilution
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1:100 (Beckman Coulter, Marseille, France). Coverslips were
then mounted in Mowiol (Sigma-Aldrich), and images re-
corded using a 63·or 100·NA objective and a Leica (Leica
Microsystems, Wetzlar, Germany) inverted microscope.
Proteome array, subcellular fractionation, and Western
blotting
The Human Phospho-Kinase array (Proteome Profiler
Array; R&D Systems, Minneapolis, MN) was used to detect
the relative phosphorylation levels of 46 kinases in p53+/+
HCT116 cellular extracts according to the manufacturer’s
protocol. To confirm the localization of the targeting mAbs, a
subcellular protein fractionation kit (Thermo Scientific) was
used according to the manufacturer’s protocol. For Western
blotting, membrane and cytosolic protein fractions and
total lysates (40 lg of each) from p53+/+ HCT116 cells and
A-431CEA were separated by sodium dodecyl sulfate poly-
acrylamide gel electrophoresis and electrotransferred to
polyvinylidene difluoride membranes (Amersham Pharmacia
Biotech, Uppsala, Sweden). Membranes were incubated with
the 35A7 (anti-CEA), m225 (anti-EGFR), sodium/potassium
ATPase (1:1000; Abcam, Cambridge, United Kingdom), and
anti-tubulin (1:10,000; Abcam) primary antibodies that were
then detected with horseradish peroxidase-conjugated goat
anti-mouse or anti-rabbit (Sigma-Aldrich) secondary anti-
bodies. p-ERK, p-AKT, and p-p38 were detected by primary
anti-p-ERK, anti-p-AKT, and anti-p-p38 antibodies (Cell
Signaling Technology, Danvers, MA) followed by incuba-
tion with horseradish peroxidase-conjugated goat anti-mouse
or anti-rabbit (Sigma-Aldrich) secondary antibodies. Proteins
were detected by enhanced chemoluminescence (ECL) using
the ECL detection system from Amersham Biosciences
(Saclay, France).
Ceramide measurement by flow cytometric analysis
Ceramide levels present in the cell membrane of p53+/+
HCT116 cells were assessed by flow cytometry. Cells were
treated with unlabeled mAbs (20 lg/ml) or 125I-mAbs
(4MBq/ml) at 37C for 1 h. After three washes, cells were
fixed in 3.7% (v/v) paraformaldehyde for 15min. Then, cells
were washed three times in PBS buffer and incubated with
the anti-ceramide 15B4 mAb at a dilution of 1:50 (Alexis
Biochemicals) at 37C for 1 h. After three washes in PBS—
2% FCS, cells were incubated with PE-conjugated goat anti-
mouse IgM at a dilution of 1:100 ( Jackson ImmunoResearch)
in the dark for 1 h. Cells were then washed three times and
suspended in PBS for analysis using a Muse flow cytometer
(Merck Millipore, Fullerton, CA). The y axis corresponds to
the total number of analyzed cells (arbitrary units), while the
x axis represents the fluorescence signal intensity (PE-
conjugated goat mAb anti-ceramide 15B4 mAb). The num-
bers provided in the red boxes correspond to the proportion of
ceramide-positive cells within the total population of cells
compared with the nontreated control.
Inhibitors of MAPK pathways and chelation
of extracellular Ca2+
To confirm the involvement of MAPK proteins, including
AKT, ERK1/2, p38, and JNK on final survival outcome,
HCT116 donor cells were incubated for 48 h with 125I-anti-
CEA mAb in the presence of 1 lM of PI3K inhibitor
(ZSTK474), and indirectly of downstream AKT signaling
pathway, 1 lM of MEK1/2 inhibitor (U0126), and indirectly
of downstream ERK1/2 signaling pathway, 10 lM of
SP600125 ( JNK inhibitor), 10 lM of SB203580 (p38 inhib-
itor), or 5mM EGTA (to chelate extracellular Ca2+ ions).
Donor cells were preincubated with inhibitors 1 h before
addition of 125I-mAbs. After 48 h, medium was removed and
standard medium transfer protocol was followed as previ-
ously described. Clonogenic survival of both donor and re-
cipient cells was measured. The efficacy of ZSTK474 and of
U0126 in inhibiting AKT and ERK1/2 was confirmed by
Western blotting (Supplementary Fig. S3B, right panel).
Measurement of ASMase activity
ASMase activity in whole cell lysates of p53+/+ HCT116
cells exposed to 125I-mAbs (0–4MBq/ml) for 2 days was
measured using the Amplex Red Sphingomyelinase Assay
Kit (Molecular Probes, Saint Aubin, France). The ASMase
activity of experimental samples and positive control was
calculated as a percentage of the ASMase activity of the
negative control.
Measurement of S1P concentration
The level of S1P was determined in p53+/+ HCT116 cells
exposed to 125I-mAbs (4MBq/ml) for 2 days using the
Sphingosine 1 Phosphate Assay Kit according to the manu-
facturer’s protocol (Echelon Biosciences, Salt Lake City, UT).
Animal model
Swiss nude mice (7-week-old females) from Charles River
were acclimated for 1 week before experimental use. They
were housed at 22C and 55% humidity with a light–dark
cycle of 12 h. Food and water were available ad libitum. Body
weight was determined weekly, and the mice were clinically
examined throughout the study. All animal experiments were
performed in compliance with the guidelines of the French
government and the INSERM standards for experimental
animal studies (agreement B34-172–27).
In vivo experiments
Swiss nude mice (7-week-old females) from Charles
River were xenografted intraperitoneally (i.p.) with
1.5 · 106 A-431CEA cells suspended in 0.3ml PBS. The A-
431CEA cell line was chosen for in vivo
125I experiments
because it expresses high levels of CEA receptors (com-
pared with HCT116 cells), which enables treatment with a
tumoricidal dose.
RIT experiments with or without MBCD. For these ex-
periments, 32 mice were divided in four groups (n = 8/each)
that were treated as follows: (i) two i.p. injections of NaCl at
day 8 and 11 postgraft, (ii) two i.p. injections of anti-CEA
mAb (100lg) at day 8 and 11, (iii) two i.p. injections of
37MBq of 125I-anti-CEA mAb at day 8 and 11, (iv) daily
i.p. injections of 300mg/kg MBCD from day 6 to 15 post-
graft, and (v) daily i.p. injections of MBCD from day 6 to 15
and two injections of 37MBq of 125I-anti-CEA mAb at day 8
and 11 postgraft. At day 30 postgraft, mice were sacrificed,
tumors collected, and the total tumor mass was determined.
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For this purpose, length, width, and depth of each tumor
nodule was measured and used for calculating the nodule
volume and a density of 1.05 g/cm3 was used to determine
each nodule mass. The average total tumor mass for each
mouse was calculated by summing up the mass value of each
nodule.
Digital autoradiography and immunohistochemical detec-
tion of 53BP1. Ten days postgraft, eight mice were injected
i.p. with 37MBq of 125I-PX or of 125I-anti-CEA mAbs. Four
and 24 h later, mice were anesthetized, bled, and dissected.
Tumors were collected and frozen after inclusion in optimal
cutting temperature embedding matrix. Two consecutive
10 lm-thick frozen sections were analyzed by digital auto-
radiography (DAR) or by immunohistochemical analysis.
DAR acquisition was performed using a Beta Imager 2000
instrument (Biospace, Paris, France) over 24 h and analyzed
using M3vision software to determine the radioactivity dis-
tribution. Immunofluorescence analysis of 53BP1 expression
was performed to assess DNA DSB formation. Frozen sec-
tions were rehydrated in PBS for 10min, fixed in 3.7% (v/v)
formaldehyde, and then permeabilized in 0.5% (v/v) Triton
X-100 for 15min followed by incubation with 10% (v/v)
PBS/BSA for 1 h. Sections were incubated at 37C with an
anti-53BP1 mAb (1:400) for 1 h followed by incubation with
an Alexa-594-conjugated anti-rabbit secondary antibody
(1:500; Invitrogen). Nuclei were stained with 0.1 lg/ml
Hoechst. The distribution of 53BP1 foci was determined in
100 cells in two relevant areas of representative tumors. All
animal experiments were performed in compliance with the
guidelines of the French government and the INSERM
standards for experimental animal studies (agreement B34-
172-27). They were approved by the local ethic committee of
‘‘Institut de Recherche en Cance´rologie de Montpellier’’
(IRCM/INSERM) and by the Ethic Committee of Languedoc
Roussillon (CEEA LR France No. 36) for animal experi-
ments under the number 1056.
Statistical analysis
All in vitro data were obtained from four independent
experiments in triplicate. Data were described using mean
and standard deviation. Analysis of variance was used for
multigroup comparisons (significance level set at a = 0.05).
Pairwise comparisons were performed using the Student’s t
test, and to control for multiple testing, the significance
threshold was set at 0.013 in these comparisons.
Data were analyzed using Stata software, version 13
(StataCorp, College Station, TX).
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Abbreviations Used
53BP1¼ p53-binding protein 1
ASMase¼ acid sphingomyelinase
CREB¼C-AMP Response Element-binding protein
DAR¼ digital autoradiography
DMSO¼ dimethyl sulfoxide
DSB¼ double-strand break
ECL¼ enhanced chemoluminescence
e-NOS¼ endothelial nitric oxide synthase
ERK¼ extracellular signal-related kinase
FAK¼ focal adhesion kinase
FCS¼ fetal calf serum
GSK3¼ glycogen synthase kinase 3
HER1¼Human Epidermal Receptor type 1
123I¼ iodine 123
125I¼ iodine 125
111In¼ indium 111
i.p.¼ intraperitoneally
IP3¼ inositol triphosphate
125I-UdR¼ 5-[(125)I]iodo-2¢-deoxyuridine
JNK¼ c-Jun N-terminal kinase
LET¼ linear energy transfer
mAb¼monoclonal antibody
MAPK¼mitogen-activated protein kinases
MBCD¼methyl-b-cyclodextrin
MSK¼mitogen- and stress-activated protein kinase
NAC¼N-acetyl cysteine
p70S6K¼ p70S6 kinase
PBS¼ phosphate buffered saline
PLC-c¼ phospholipase C-c
PYK-2¼ proline-rich tyrosine kinase 2
RIT¼ radioimmunotherapy
RNS¼ reactive nitrogen species
ROS¼ reactive oxygen species
RSK¼ 90kDa ribosomal S6 kinase
S1P¼ sphingosine-1-phosphate
STAT1/2/3/4¼ signal transducer and activator of
transcription 1/2/3/4
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